Skip to content

CLLS - Cellectis S.A. - AlphaYou

Discover Compare Pricing

Sign in Sign up

Home Smart money Buy calls Analyze

Back to stock searchC

Cellectis SA

CLLS · NASDAQ

Save to watchlist

Price is syncing

Reported smart-money activity for this stock is still below.

C

CLLSCellectis SA

Overview

No source-backed view yet. This page is available for price, fundamentals, and future receipts as coverage warms.

Key stats

Aug 20

52-wk high: $5.48
52-wk low: $2.35
Prev close: $4.36
Mkt cap: $319.2M
Beta: 2.75
P/S: 5.0x

Smart money

5 funds hold a position.

Real smart money

Funds holding this stock

5 holders

Combined position$1.1M

CI
Citadel
Ken Griffin · Q1 2026 13F
$140K
position
P7
Point72
Steven Cohen · Q4 2025 13F

Earnings

Reported Aug 6, 2026

Earnings came in 12.0% above what analysts expected.

Documents

Quarterly report10-Q Annual report10-K

Financials

Fundamentals

Is the business strong?

This company is not yet profitable.

Net margin: -102.3%
Market cap: $319M

Valuation

P/S5.00
P/B7.45

Quality

Operating margin-340.7%
ROE

Technicals

Technicals

Price structure

No data yet

Technicals sync when verified market data is available. No sample data is shown.

Company

Symbol: CLLS
Exchange: NASDAQ
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Market cap: $319.22M
Beta: 2.75

Analysts

What do analysts expect?

Analyst target and ratings are on paid plans

See the 12-month consensus target and the buy/hold/sell rating split.

Unlock the full results

Research hubs
About
Editorial policy
Methodology
Source coverage
Corrections

Privacy
Terms
Refunds
Disclaimer

© 2026 AlphaYou. All rights reserved.Not financial advice. Do your own research. Informational data only; past performance does not predict future results.

P/B

7.5x

Profit margin

-102.3%

Op margin

-340.7%

ROE

-94.5%

$132K

position

MW

Marshall Wace

Q1 2026 13F

$130K

position

2 more holders

Lite opens all of them for $16.50/month, paid yearly.

Unlock all 2 holders

Coverage gaps for CLLS

No recent insider trade
No recent Congress trade
No recent market-voice mention

Earnings per share

-$0.22+12.0%

-$0.25 expected

Next report

What the street expects next

EPS expected

-$0.20

-$0.23 to -$0.15

Revenue expected

$13.1M

5 analysts

Last 30 days

2up0down

Analysts raising estimates

Estimate drift

+0.02

Change in 30 days

-94.5%

ROA-11.7%

Growth

Beta2.75